NASDAQ:ATYR aTyr Pharma Q3 2025 Earnings Report $0.37 +0.01 (+3.25%) As of 03:47 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast aTyr Pharma EPS ResultsActual EPS-$0.26Consensus EPS -$0.20Beat/MissMissed by -$0.06One Year Ago EPSN/AaTyr Pharma Revenue ResultsActual Revenue$0.19 millionExpected Revenue$0.91 millionBeat/MissMissed by -$719.00 thousandYoY Revenue GrowthN/AaTyr Pharma Announcement DetailsQuarterQ3 2025Date11/6/2025TimeBefore Market OpensConference Call DateThursday, November 6, 2025Conference Call Time4:00PM ETUpcoming EarningsaTyr Pharma's Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 6, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsEarnings Release(8-K)Quarterly Report(10-Q) aTyr Pharma Earnings HeadlinesaTyr Pharma (NASDAQ:ATYR) Stock Price Down 9.6% - Should You Sell?September 15, 2026 | americanbankingnews.comSarcoidosis Market Forecast: Emerging Therapies and Increasing Disease Awareness to Drive Expansion by 2036 | DelveInsightSeptember 8, 2026 | finance.yahoo.comMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up Amazon and Netflix under $3 per share in 2005. Now the chief investment strategist at The Oxford Club has identified three AI stocks he believes could be the most profitable investments of the next decade.September 23 at 1:00 AM | The Oxford Club (Ad)ATyr Provides Tentative FDA Timeline For Phase 3 Efzofitimod In Lung DiseaseSeptember 2, 2026 | rttnews.comaTyr Pharma Updates Timing of FDA Response for Planned Phase 3 Trial of EfzofitimodSeptember 2, 2026 | finance.yahoo.comaTyr Pharma Provides Update on FDA Response Timing for Planned Phase 3 Efzofitimod Sarcoidosis StudySeptember 1, 2026 | quiverquant.comQSee More aTyr Pharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like aTyr Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on aTyr Pharma and other key companies, straight to your email. Email Address About aTyr PharmaaTyr Pharma (NASDAQ:ATYR) (NASDAQ: ATYR) is a biotechnology company focused on developing therapies that modulate immune responses and address serious inflammatory diseases. The company’s research is based on its Physiocrine biology platform, which explores the therapeutic activity of extracellular domains of tRNA synthetases, a group of proteins involved in regulating biological processes beyond protein synthesis. aTyr’s lead product candidate is efzofitimod, an engineered version of a naturally occurring protein intended to regulate immune-cell activity and reduce inflammation. The candidate has been studied primarily as an inhaled treatment for pulmonary sarcoidosis, a rare inflammatory lung disease, and has also been evaluated in other interstitial lung disease settings, including systemic sclerosis-associated interstitial lung disease. Founded in 2005 and headquartered in San Diego, California, aTyr conducts research and clinical development activities through collaborations and clinical studies involving patients and medical institutions in the United States and other regions. The company is led by Sanjay S. Shukla, M.D., M.S., who serves as president and chief executive officer.View aTyr Pharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Energy Transfer Taps the AI Power BoomFull Throttle: Kratos and GE Fire Up a Next-Gen Defense EngineSandisk Joins the S&P 100—Is the Index Flow, or the AI Story, Driving the Stock?Thor Industries Is Boring—And That May Be Its Biggest AdvantageAutoZone Shifts Gears, On Track to Reverse Course and Price RecoveryMeta’s Muse Highlights Arm’s Growing Role in AI InfrastructureOld Dogs, New Tech: 3 Legacy Stocks Powering the AI Boom Upcoming Earnings Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
